Log In


All News

Sort By News Date & Time Sort Descending Order News Source News Title

  Refine Search  
Date Range
News Type

22/06/2015 6:07PM

Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study

Results from an interim analysis of the Phase III RE-VERSE AD™ patient study demonstrate that 5 g of idarucizumab* immediately reversed the anticoagulant effect of dabigatran (Pradaxa®) in patients requiring ...

03/06/2015 2:40PM

NICE recommends VARGATEF® (nintedanib*) in combination with docetaxel as an option for patients with non-small cell lung cancer of adenocarcinoma histology within its licensed indication

Boehringer Ingelheim today announced that following a review by the National Institute for Health and Care Excellence (NICE) in the UK, VARGATEF® (nintedanib*) in combination with docetaxel has been recommended for ...

08/06/2015 1:00PM

Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care

New research shows that the quality of patient-physician communication, at the moment when additional oral type 2 diabetes (T2D) medication is prescribed (‘add-on’), is linked to future patient self-care and ...

08/06/2015 1:03PM

Type 2 diabetes: Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA

A Phase III clinical trial has found that empagliflozin in combination with metformin reduces blood glucose levels in adults with type 2 diabetes (T2D). Boehringer Ingelheim and Eli Lilly and Company presented these ...

02/07/2015 12:00PM

New advance in COPD maintenance treatment, Spiolto® Respimat®, approved in first European countries  

Boehringer Ingelheim today announced regulatory authority approvals for Spiolto® Respimat® (tiotropium/olodaterol) in first European countries†. Spiolto® Respimat® is a once-daily maintenance ...

06/07/2015 3:40PM

Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) (...)

Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) in patients with previously treated advanced squamous cell ...

16/07/2015 10:40AM

Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim welcomes the international evidence-based 2015 ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis – An Update of the 2011 Guideline which suggests that ...

29/07/2015 10:00AM

Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer

Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd has announced an exclusive license and collaboration agreement for the development and global commercialisation rights, except South Korea, China and Hong Kong, of ...